viewFutura Medical PLC

Futura Medical phase III trial on track to begin in September; out-licensing agreement "remains a top priority"

The company's flagship product is a fast-acting gel for erectile dysfunction

The company's condom range received regulatory sign-off in Kuwait recently

The phase III clinical trial of Futura Medical PLC's (LONFUM) fast-onset gel for erectile dysfunction is on track for first patient dosing in September, chairman John Clarke confirmed ahead of the company's annual meeting later.

He added that the completion of a significant out-licensing agreement for MED2002 "remains a top priority" as he investors were told: "Whilst negotiations proceed, we will continue to maintain the momentum in the product's development.

READ: Futura Medical starts work on Phase III trial for its erectile dysfunction gel

In an update on progress, Clarke said preparations for the launch of its CSD500 condom in new territories were underway after it received regulatory sign-off in Kuwait and with the product now on sale in Saudi Arabia. 

On TPR100, Futura's diclofenac gel for pain relief, the chairman said the company was waiting for the manufacturer Thornton & Ross to submit its UK regulatory dossier to the Medicines & Healthcare products Regulatory Agency.

"Futura has a strong balance sheet, an experienced team, an exciting product portfolio and a particularly valuable asset in MED2002, which has the potential to be the world's fastest-acting erectile dysfunction treatment," said Clarke.  

"We look forward to providing further updates in the current financial year."


Quick facts: Futura Medical PLC

Price: 15.665 GBX

Market: AIM
Market Cap: £38.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...



Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18

2 min read